基因检测：99美元/人份目标，可能挑战医学模式

    作为“量化自身”（Quantified Self）运动的主要赞助者，融合在线工具+社交网络+众包模式于一体的基因检测先驱 -23andMe  ，新融资5千万美元，其创始人 Anne Wojcicki （Google创始人的太太）宣布：100万用户，99美元的新目标！
    如果这一目标实现，将极大推动个性化医疗的发展，开创医学新时代。未来遗传背景与环境相互作用对疾病的发生、发展的影响，以及个性化用药或成为主流。同样，循证医学理论模式、疾病指南模式也会面临一定的挑战。当然，循证医学模式也可能与个性化用药模式也能达到完美的融合。

23andMe, a wonderful annual sponsor of the Quantified Self, has some exciting news to share with us. Check out this letter from 23andMe’s CEO Anne Wojcicki below!

–

Today we’re announcing some big news. I don’t want this moment to go by without a note of gratitude to our customers and those who have been advocates for 23andMe over the years.

We have come a long way together.  Because of you we pioneered the use of personal genetics.  You are helping us establish a new medical era that is defined by wellness, disease prevention, and personalized care.  You also helped us create a novel research platform.  By leveraging online tools, social networking and crowd sourcing, and combining them with genetics, we created a platform that has set the stage to transform the way pharma companies and academics do health and wellness research.

We want to do more.

23andMe has raised more than $50 million in new financing with the goal of reaching one million customers.  To help us reach our goal, we are happy to announce today, that we are dropping our price to $99.

One million customers can be the tipping point that moves medicine into the molecular era.  Hundreds of you have written to us about how genetic information changed your lives and, in some cases, saved your lives.  We believe genetics should be an integral part of health care and we will work hard in the coming year to help genetics become part of everyone’s health and wellness.

A community of one million individuals will also benefit the world.  A genetic data resource of this magnitude has enormous potential to address unanswered questions related to the contributions of genes, the environment and your health.  Understanding these factors and their interactions could lead to major improvement in diagnostics, preventive medicine and therapeutics [Collins NATURE | VOL 429 | 27 MAY 2004].

This change is not just about a new price point for personal genetic testing. It is about an ambitious plan that could transform medicine for generations to come.